PharmaDeals Corp-METRx provides vital company metrics that enable comparison of the top 12 Pharmaceutical Companies deal strategies and activities.
Deal Performance Analytics and Index
Covering overall licensing and M&A activity (short and long term), therapeutic focus, plus deal activity relative to R&D spend, this is a key resource for all executives and analysts within biotechnology, pharmaceutical and the financial services sectors.
- Which of the top 12 is the deal making leader for different therapeutic areas.
- Who is striking the most deals in the short term.
- How do they rank in terms of their long term deal strategies.
- Who are the most acquisitive in the M&A sector
- How are these companies balancing internal and external pipeline filling.